Anti-Sclerostin antibody [MM0556-9N13] (ab89733)

Overview

  • Product name
    Anti-Sclerostin antibody [MM0556-9N13]
    See all Sclerostin primary antibodies
  • Description
    Mouse monoclonal [MM0556-9N13] to Sclerostin
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant full length Human Sclerostin

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    Preservative: None
    Constituents: PBS
  • Concentration information loading...
  • Purity
    Protein G purified
  • Purification notes
    The IgG fraction of culture supernatant was purified by Protein G affinity chromatography and filtered through a 0.2 µm filter.
  • Clonality
    Monoclonal
  • Clone number
    MM0556-9N13
  • Isotype
    IgG2
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab89733 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Predicted molecular weight: 24 kDa.

Target

  • Function
    Negative regulator of bone growth.
  • Tissue specificity
    Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteeoblasts differentiated for 21 days.
  • Involvement in disease
    Defects in SOST are the cause of sclerosteosis (SOST) [MIM:269500]; also known as cortical hyperostosis with syndactyly. SOST is an autosomal recessive sclerosing bone dysplasia characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients.
    Note=A 52 kb deletion downstream of SOST results in SOST transcription suppression and is a cause of van Buchem disease (VBCH) [MIM:239100]; also known as hyperostosis corticalis generalisata. VBCH is an autosomal recessive sclerosing bone dysplasia characterized by endosteal hyperostosis of the mandible, skull, ribs, clavicles, and diaphyses of the long bones. Affected patients present a symmetrically increased thickness of bones, most frequently found as an enlarged jawbone, but also an enlargement of the skull, ribs, diaphysis of long bones, as well as tubular bones of hands and feet. The clinical consequence of increased thickness of the skull include facial nerve palsy causing hearing loss, visual problems, neurological pain, and, very rarely, blindness as a consequence of optic atrophy. Serum alkaline phosphatase levels are elevated.
  • Sequence similarities
    Belongs to the sclerostin family.
    Contains 1 CTCK (C-terminal cystine knot-like) domain.
  • Cellular localization
    Secreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • BEER antibody
    • CDD antibody
    • Cortical hyperostosis with syndactyly antibody
    • Sclerosteosis antibody
    • Sclerostin antibody
    • Sost antibody
    • SOST_HUMAN antibody
    • SOST1 antibody
    • UNQ2976/PRO7455/PRO7476 antibody
    • VBCH antibody
    see all

References for Anti-Sclerostin antibody [MM0556-9N13] (ab89733)

ab89733 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab89733.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up